Syneron Bio
Both parties publicly confirmed the AstraZeneca collaboration. A 2026 financing announcement states that proceeds will advance the pipeline into clinical development; specific human oral PK data were not disclosed.
ChinaFull profile →
Find your next research lead.
All cataloged profiles, sources, filters, and comparisons are open. Sign in to save companies, keep private notes, and join discussions.
471 company identities · 13 technology & service fields
Disease tags identify mentions in recorded facts or pipeline text, not approved indications or a complete pipeline. Platform service providers may have no disease-specific tag.
10 matching companies
Oralead Pharma
The company website confirms the Macoral® / Simgut® platform and collaboration with BrightGene. The pipeline image reviewed is historical; current clinical stages require confirmation.
ChinaFull profile →
Unnatural Products
Iterative design, synthesis, and experimental optimization improve synthetic macrocyclic peptide potency, selectivity, and permeability. The company collaborates with argenx on oral macrocycle programs.
United StatesFull profile →
Pinnacle Medicines
Uses AI, physics-based simulation, peptide chemistry, and oral formulation development for oral immunology and cardiometabolic peptides; operates in Shanghai and Pennsylvania.
China / United StatesFull profile →
Orbis Medicines
nGen combines AI and automated synthesis to optimize oral properties of nCycles and has a multi-target cardiometabolic collaboration with Novo. The company describes nCycles as fully synthetic macrocyclic NCEs.
丹麦 / SwitzerlandFull profile →
PeptiDream / ペプチドリーム
The PDPS-derived oral peptide pipeline includes a myostatin program listed as IND-enabling, plus other oral candidates; it is recorded separately from the radiopharmaceutical peptide pipeline.
JapanFull profile →
Inventage Lab / 인벤티지랩
The company disclosed a patent for an oral semaglutide nanoparticle formulation. This is a noncyclic peptide delivery reference, not clinical validation for cyclic peptides.
South KoreaFull profile →
Ensol Biosciences / 엔솔바이오사이언스
The website separately describes H1K, an oral anti-obesity candidate, and ESAIDD cyclic peptide discovery. This review could not confirm that H1K is cyclic or has human results.
South KoreaFull profile →
Novo Nordisk
Works with Orbis on oral macrocycle discovery and with Vivtex on delivery. Success with oral semaglutide does not automatically validate the collaborative macrocycle program.
Merck / MSD
LIPFENDRA is a U.S.-approved oral PCSK9 inhibitor. Its label confirms sodium caprate and approximately 1% oral bioavailability.
United StatesFull profile →
Coverage expands from sourced records; this database does not claim all biopharma companies.